5-Amino-1MQ

5-Amino-1-methylquinolinium is a potent NNMT (Nicotinamide N-methyltransferase) inhibitor that modulates cellular metabolism through epigenetic and bioenergetic mechanisms. NNMT normally diverts SAM (S-adenosylmethionine) toward methylation of nicotinamide, reducing NAD+ precursor availability. By inhibiting NNMT, 5-Amino-1MQ increases intracellular SAM, upregulates NAD+ biosynthesis, and activates sirtuin pathways in fat tissue, making it a valuable research tool for adipogenesis inhibition and metabolic rate enhancement studies.

This small molecule N-methylquinolinium derivative (MW 158.2 g/mol; C10H12N2) functions through a unique mechanism distinct from direct NAD+ supplementation. Rather than providing exogenous NAD+ precursors, it preserves endogenous NAD+ biosynthesis capacity by blocking the enzymatic pathway that depletes NAD+ precursors. This upstream intervention creates sustained elevation of intracellular NAD+ levels and enhanced sirtuin activity, particularly in adipose tissue where NNMT expression is highest.

In research applications, 5-Amino-1MQ demonstrates the ability to reduce adipocyte size, enhance metabolic rate, and improve insulin sensitivity through NNMT inhibition and subsequent NAD+/sirtuin pathway activation. The compound increases cellular energy expenditure and promotes a metabolic shift toward enhanced fat oxidation. Studies document oral bioavailability in mouse models, distinguishing it from peptide-based metabolic research compounds.

The mechanism extends beyond simple NAD+ elevation to include epigenetic modulation through increased SAM availability. Elevated SAM enhances methylation capacity, potentially influencing gene expression programs related to adipogenesis, mitochondrial biogenesis, and metabolic regulation. This dual action on both NAD+ biosynthesis and methylation capacity makes it a comprehensive metabolic research tool.